53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04968912 (ClinicalTrials.gov) | September 21, 2021 | 9/7/2021 | A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) | A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) | Sjogren's Syndrome | Other: Placebo;Drug: Nipocalimab;Drug: Standard of Care Treatment | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | 75 Years | All | 150 | Phase 2 | United States;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan |